Healthcare -
Biotechnology - NASDAQ - US
$ 16.635
4.43 %
$ 2.84 B
Market Cap
-5.87
P/E
1. INTRINSIC VALUE
Balance Sheet
Immunovant, Inc.
| Current Assets | 768 M |
| Cash & Short-Term Investments | 714 M |
| Receivables | 2.08 M |
| Other Current Assets | 51.6 M |
| Non-Current Assets | 8.56 M |
| Long-Term Investments | 0 |
| PP&E | 942 K |
| Other Non-Current Assets | 7.62 M |
| Current Liabilities | 68.8 M |
| Accounts Payable | 17.7 M |
| Short-Term Debt | 98 K |
| Other Current Liabilities | 51 M |
| Non-Current Liabilities | 0 |
| Long-Term Debt | 0 |
| Other Non-Current Liabilities | 0 |
EFFICIENCY
Earnings Waterfall
Immunovant, Inc.
| Revenue | 0 |
| Cost Of Revenue | 0 |
| Gross Profit | 0 |
| Operating Expenses | 438 M |
| Operating Income | -438 M |
| Other Expenses | -24.3 M |
| Net Income | -414 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Immunovant, Inc.
| Net Income | -414 M |
| Depreciation & Amortization | 377 K |
| Capital Expenditures | -759 K |
| Stock-Based Compensation | 49.5 M |
| Change in Working Capital | -12 M |
| Others | 49.6 M |
| Free Cash Flow | -377 M |
Wall Street Analysts Price Targets
Immunovant, Inc.
Wall Street analysts predict an average 1-year price target for IMVT of $50.5 , with forecasts ranging from
a
low of
$46 to a high of $57 .
IMVT Lowest Price Target
Wall Street Target
46 USD
176.53%
IMVT Average Price Target
Wall Street Target
50.5 USD
203.58%
IMVT Highest Price Target
Wall Street Target
57 USD
242.65%
4. DIVIDEND
ANALYSIS
IMVT does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Immunovant, Inc.
Sold
0-3 MONTHS
597 K USD 4
3-6 MONTHS
1.24 M USD 6
6-9 MONTHS
2.2 M USD 8
9-12 MONTHS
2.09 M USD 7
Bought
0 USD 0
0-3 MONTHS
337 M USD 1
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Immunovant (IMVT) Upgraded to Buy: What Does It Mean for the Stock?
Immunovant (IMVT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
zacks.com
- 2 weeks ago
IMVT Q4 Loss Narrower Than Expected, Stock Up, Pipeline in Focus
Immunovant stock rises on encouraging fourth-quarter fiscal 2025 results. It is on track to initiate 10 studies on IMVT-1402 across various autoimmune indications.
zacks.com
- 2 weeks ago
Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025
Immunovant's new management team is focused on rapid clinical execution for the six announced indications for IMVT-1402, including a second potentially registrational study in Graves' disease (GD) and a potentially registrational study in Sjögren's disease (SjD), both expected to start in summer 2025 Positive data from first-generation batoclimab trials in myasthenia gravis (MG) and chronic inflammatory demyelinating polyneuropathy (CIDP) demonstrated that deeper IgG reductions correlated with improved clinical outcomes across a range of assessments and timepoints suggesting a potential best-in-class efficacy profile for IMVT-1402 Current cash balance provides runway for announced indications through GD readout expected in 2027 NEW YORK, May 29, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported corporate updates and financial results for its fourth quarter and fiscal year ended March 31, 2025. Recent Highlights and Upcoming Milestones: In April 2025, Immunovant announced changes to its leadership team as part of a broader strategic transition with Roivant increasing operational involvement and oversight of Immunovant.
globenewswire.com
- 3 weeks ago
IMVT INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Announces Investigation into a Private Placement Transaction by Immunovant, Inc. and Encourages Investors to Contact the Firm
SAN DIEGO--(BUSINESS WIRE)--Robbins Geller Rudman & Dowd LLP announces an investigation into potential breaches of fiduciary duty by the directors and officers of Immunovant, Inc. (NASDAQ: IMVT) and Roivant Sciences Ltd. – Immunovant's controlling stockholder – in connection with Immunovant's January 2025 private placement transaction in which Roivant purchased nearly 16.9 million Immunovant shares at a price of $20.00 per share, a $3.48 per share discount to the prior trading day's closing.
businesswire.com
- 4 weeks ago
Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren's Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402
NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced next phase of growth including changes to its leadership team and the expanded development of IMVT-1402 into two new indications, SjD and CLE.
globenewswire.com
- 1 month ago
Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren's Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402
Eric Venker, M.D. (currently President and COO of Roivant) appointed as CEO of Immunovant and Tiago Girao appointed as CFO of Immunovant Pete Salzmann, M.D.
globenewswire.com
- 1 month ago
IMVT Unlikely to Pursue Batoclimab for MG & CIDP Despite Success
Immunovant's batoclimab shows strong efficacy in MG & CIDP, but shifts focus to the lead drug IMVT-1402 for these indications to induce deeper, lasting relief.
zacks.com
- 2 months ago
Immunovant: TED Data Sets Stage For Batoclimab Regulatory Filings Going Forward
Immunovant, Inc. reported that positive results were achieved using batoclimab in a phase 3 study to target patients with Myasthenia Gravis; Primary endpoint met. Positive results achieved using batoclimab in phase 2b study targeting patients with Chronic Inflammatory Demyelinating Polyneuropathy; IgG was reduced by ≥ 70%. Data from both phase 3 studies, using batoclimab to treat patients with Active Thyroid Eye Disease, expected 2nd half of 2025.
seekingalpha.com
- 3 months ago
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Immunovant, Inc. (NASDAQ: IMVT)
NEW YORK , March 19, 2025 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Immunovant, Inc. (NASDAQ: IMVT) on behalf of the company's shareholders. The investigation seeks to determine whether Immunovant's directors breached their fiduciary duties in connection with recent corporate actions.
prnewswire.com
- 3 months ago
Roivant, Immunovant Succeed In Phase 3. But There's A Twist — And Shares Tumbled.
Immunovant and Roivant Sciences said Wednesday their rare disease drug succeeded in a final-phase study, but the duo won't seek approval. The post Roivant, Immunovant Succeed In Phase 3.
investors.com
- 3 months ago
Immunovant's muscle disorder treatment meets main goal in late-stage trial
Immunovant said on Wednesday its drug for a type of a chronic autoimmune disease that causes muscle weakness met the main goal in a late-stage trial.
reuters.com
- 3 months ago
Immunovant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies
NEW YORK, March 19, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported topline results from its Phase 3 study of batoclimab in MG and initial results from Period 1 of its Phase 2b study in CIDP.
globenewswire.com
- 3 months ago
8. Profile
Summary
Immunovant, Inc. IMVT
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 2.84 B
Dividend Yield
0.00%
Description
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
Contact
320 West 37th Street, New York City, NY, 10018
https://immunovant.com
IPO
Date
June 21, 2019
Employees
362
Officers
Mr. Tiago M. Girao CPA
Chief Financial Officer
Ms. Christine Blodgett
Senior Vice President of Human Resources
Mr. Andy Deig
Senior Vice President of Strategic Finance
Ms. Melanie Gloria B.S.N.
Chief Operating Officer
Ms. Lauren Schrier M.B.A.
Vice President of Marketing
Dr. Michael Geffner M.B.A., M.D., Ph.D.
Chief Medical Officer
Dr. Jay S. Stout Ph.D.
Chief Technology Officer
Dr. Frank M. Torti M.B.A., M.D.
Executive Chairperson of the Board
Dr. Eric Venker M.D., Pharm.D.
Chief Executive Officer & Director
Mr. Christopher A. Van Tuyl Esq., J.D.
Chief Legal Officer & Corporate Secretary